01-08-2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
Published in: Investigational New Drugs | Issue 3/2004
Login to get access01-08-2004
Published in: Investigational New Drugs | Issue 3/2004
Login to get access